Disease introduction

Parkinson’s disease is a degenerative disorder of the central nervous system that results in the deterioration of the patient’s motor skills, speech and other functions. Some patients may be unable to control their disease effectively with prescribed medication, resulting in unpredictable "on/off" fluctuations.

Treatment of Parkinson’s disease

Apomorphine hydrochloride is used to treat Parkinson’s disease. It is often prescribed to patients who are not responding well to other treatments or who experience frequent “off” periods and less control. The drug acts quickly and reliably, meaning those that need to be active at specific times can continue with their normal activities.

Apomorphine is administered subcutaneously:

  • By intermittent injections with a ready-loaded disposable pen
  • As a continuous infusion using a syringe driver infusion pump with a pre-filled syringe

Infusion therapy with apomorphine

The patient uses a battery-driven, syringe driver infusion pump to deliver a specified continuous amount of the drug when required, adjusting the amount as needed during the day.

To deliver apomorphine, the patient inserts an infusion set under the skin and connects it to the infusion pump. The patient needs to change the infusion set at least once a day.

Elderly couple



The neria™ product range

neria™ infusion sets are approved and used for continuous infusion treatment for Parkinson’s Disease.1

The neria™ product range offers a wide variety of infusion sets with different features to help provide the best possible treatment for patients with Parkinson's Disease.

neria™ infusion sets are infusion devices developed specifically for subcutaneous infusion of medication and are tested (in vitro) for use with apomorphine.1

For a complete overview of our neria™ infusion set range, including specifications, please see the table below. The table is also available as a pdf download.

Product Specifications neria™ neria™ detach neria™ multi neria™ soft neria™ soft 90 neria™ guard
Cannula Stainless Steel Stainless Steel Stainless Steel Soft Soft Soft
Insertion angle 90 degrees 90 degrees 90 degrees 20-45 degrees 90 degrees 90 degrees
Disconnection feature No Yes No Yes at site Yes at site Yes at site
Needle / Introducer needle guage G27 or G29 G27 G27 G27 G27 G27
Needle lengths 6, 8, 10 or 12 mm 6,8 or 10mm Bi-furcated: 8, 10mm
Tri-furcated: 8, 10 or 12mm
Quad-furcated: 8, 10, 12mm
13 or 17mm 6 or 9 mm 6 or 9 mm
Tubing lengths 60, 80, 110 cm 60, 80, 110 cm Total 90 cm 30, 60, 80, 110 cm 30, 60, 110 cm 12, 30, 60, 80, 110 cm
Adhesive Built-in Built-in Built-in Built-in Built-in Built-in
Needle safety - - - - Yes Yes
Priming volumes 60 cm @ 0.10 ml
80 cm @ 0.12 ml
110 cm @ 0.15 ml
60 cm @ 0.10 ml
80 cm @ 0.12 ml
110 cm @ 0.15 ml
Bi-furcated ~ 0.36 ml
Tri-furcated ~ 0.43 ml
Quad-furcated ~ 0.51 ml
30 cm @ 0.06 ml
60 cm @ 0.10 ml

80 cm @ 0.12 ml
110 cm @ 0.15 ml
30 cm @ 0.06 ml
60 cm @ 0.10 ml

110 cm @ 0.15 ml
12 cm @ 0.04 ml
60 cm @ 0.10 ml

80 cm @ 0.12 ml
110 cm @ 0.15 ml


1. Statement - Overview of Drug/Device Compatibility Test for the neria™ Range. 24. February 2020. AP-020446-MM. Data on file. Unomedical A/S.





Find relevant clinical literature about Parkinson's Disease and continuous subcutaneous infusion management below:

Poster discussing subcutaneous drug delivery and nodule prevention.

Sinclair, M. Bendixen and P. K. Schøndorff, 2018


Regina Katzenschlager, Werner Poewe, Olivier Rascol, Claudia Trenkwalder, Günther Deuschl, K Ray Chaudhuri, Tove Henriksen, Teus van Laar,Kevin Spivey, Senthil Vel, Harry Staines, Andrew Lees

Lancet Neurol 2018; 17: 749–59


Sophie Drapier,  Alexandre Eusebio, Bertrand Degos, Marc Ve´rin, Franck Durif,  Jean Philippe Azulay, Francois Viallet, Tiphaine Rouaud, Caroline Moreau, Luc Defebvre, Valerie Fraix, Christine Tranchant, Karine Andre, Christine Brefel Courbon, Emmanuel Roze, David Devos

J Neurol 2016; 263(6): 1111-9


Roongroj Bhidayasiri, Pedro J. Garcia Ruiz, Tove Henriksen

Parkinsonism and Related Disorders 33 (2016) S42-S48


Tove Henriksen

Neurodegener Dis Manag. 2014;4(3):271-82


Amy Todd, Cherry-Ann James

British journal of community nursing 2008; 13(10):457-63

LINK ABSTRACT:  https://pubmed.ncbi.nlm.nih.gov/19057470/